What's Happening?
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to calderasib (MK-1084), an investigational KRAS G12C inhibitor developed by Merck, for the treatment of patients with advanced or metastatic non-small cell lung
cancer (NSCLC) with KRAS G12C mutation and PD-L1 expression. This designation is based on positive data from the Phase 1 KANDLELIT-001 trial. Calderasib is being developed in collaboration with Taiho Pharmaceutical Co. Ltd. and Astex Pharmaceuticals. The Breakthrough Therapy designation aims to expedite the development and review of drugs that show substantial improvement over existing therapies for serious conditions.
Why It's Important?
The designation of calderasib as a Breakthrough Therapy highlights its potential to address unmet medical needs in treating KRAS G12C-mutated NSCLC, a condition with limited treatment options. This mutation is prevalent in approximately 14% of NSCLC patients, making it a significant target for new therapies. The designation could lead to faster development and availability of calderasib, potentially improving outcomes for patients with this specific genetic mutation. The collaboration between Merck and its partners underscores the importance of joint efforts in advancing cancer treatment.
What's Next?
Merck plans to continue the development of calderasib through the KANDLELIT clinical program, which includes multiple Phase 3 trials across various tumor types and stages. These trials will evaluate calderasib in combination with other therapies, such as KEYTRUDA and cetuximab, to determine its efficacy and safety in broader patient populations. The Breakthrough Therapy designation will facilitate more intensive guidance from the FDA, potentially leading to a streamlined approval process.
